相关实验视频
Updated: May 28, 2025
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
49.8K
甲胺抑制了马达尔塔T17细胞分化,缓解了DSS诱导的大肠炎
Mingzhong Sun1, Hongli Liu2, Huixiang Ju1
1Department of Laboratory Medicine, Affiliated Hospital 6 of Nantong University, Yancheng Third People' S Hospital, The Yancheng School of Clinical Medicine of Jiangsu Vocational College of Medicine, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng, 224000, Jiangsu, China.
Immunologic research
|February 11, 2025
概括
甲福明是一种抗炎药物,通过抑制称为 γδT17 细胞的特定免疫细胞来减少小鼠的性结肠炎 (UC) 症状. 这表明了UC的新治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 甲福明表现出抗炎作用,并影响肠道微生物群.
- γδT17细胞是肠道炎症的关键驱动因素,但甲胺对它们的影响尚不清楚.
研究的目的:
- 调查大肠炎模型中甲福明治疗效果与 γδT17 细胞活性之间的联系.
- 评估抑制gδT17细胞在美特福林抗结肠炎作用中的作用.
- 探索甲胺对γδT17细胞分化及其潜在机制的影响.
主要方法:
- 利用小鼠模型的硫酸 (DSS) 诱导的大肠炎.
- 服用甲福明并评估其对大肠炎严重程度和γδT17细胞群的影响.
- 进行了体外实验,以检查甲福明对γδT17细胞分化和信号通路 (mTOR/RORγt) 的影响.
主要成果:
- 在DSS诱导的大肠炎小鼠中,甲福明治疗与减少的γδT17细胞积累相关.
- 引入外源的 γδT17 细胞抵消了甲福林对大肠炎的保护作用.
- 甲福明抑制了γδT17细胞分化,与抑制的mTOR/RORγt活性有关.
结论:
- 甲福明通过抑制γδT17细胞分化来改善小鼠大肠炎的症状.
- 抑制γδT17细胞代表了性结肠炎中甲福林的潜在治疗机制.
- 需要进一步的研究,以充分阐明甲胺抑制γδT17分化的机制.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
160
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
160
01:29Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
01:23Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
94
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
94
01:17Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140